Shakeri A, Adanty C. Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: A review. J Popl Ther Clin Pharmacol [Internet]. 2020 Jan. 6 [cited 2025 Oct. 11];27(1):e25-e31. Available from: https://www.jptcp.com/index.php/jptcp/article/view/655